Effect of fluoxetine on planktonic and biofilm growth and the antimicrobial susceptibility of Burkholderia pseudomallei

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Limmathurotsakul D, Golding N, Dance DAB et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat. Microbiol. 1(1), 15008 (2016).
  CASGoogle Scholar
• 2. Benoit TJ, Blaney DD, Doker TJ et al. A review of melioidosis cases in the Americas. Am. J. Trop. Med. Hyg. 93(6), 1134–1139 (2015).
  Medline CASGoogle Scholar
• 3. Brilhante RSN, Bandeira TJPG, Cordeiro RA et al. Clinical–epidemilogical features of 13 cases of melioidosis in Brazil. J. Clin. Microbiol. 50(10), 3349–3352 (2012a).
  MedlineGoogle Scholar
• 4. Dance D, Davong V, Soeng S et al. Trimethoprim/sulfamethoxazole resistance in Burkholderia pseudomallei. Int. J. Antimicrob. Agents 44(4), 368–369 (2014).
  Medline CASGoogle Scholar
• 5. Brilhante RSN, Valente LGA, Rocha MFG et al. Sesquiterpene farnesol contributes to increased susceptibility to β-lactams in strains of Burkholderia pseudomallei. Antimicrob. Agents Chemother. 56(4), 2198–2200 (2012b).
  Medline CASGoogle Scholar
• 6. Castelo-Branco DS, Riello GB, Vasconcelos DC et al. Farnesol increases the susceptibility of Burkholderia pseudomallei biofilm to antimicrobials used to treat melioidosis. J. Appl. Microbiol. 120(3), 600–606 (2016).
  Medline CASGoogle Scholar
• 7. Limmathurotsakul D, Paeyao A, Wongratanacheewin S et al. Role of Burkholderia pseudomallei biofilm formation and lipopolysaccharide in relapse of melioidosis. Clin. Microbiol. Infect. 20(11), 854–856 (2014). • Shows the importance of biofilm production for bacterial virulence and resitance.
  MedlineGoogle Scholar
• 8. Munoz-Bellido JL, Munoz-Criado S, García-Rodríguez JA. Antimicrobial activity of psychotropic drugs selective serotonin reuptake inhibitors. Int. J. Antimicrob. Agents 14(3), 177–80 (2000).
  Medline CASGoogle Scholar
• 9. Kaatz GW, Moudgal VV, Seo SM, Kristiansen JE. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 47(2), 719–726 (2003).
  Medline CASGoogle Scholar
• 10. Kvist M, Hancock V, Klemm P. Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl. Environ. Microbiol. 74(23), 7376–7382 (2008).
  Medline CASGoogle Scholar
• 11. Bohnert JA, Szymaniak-Vits M, Schuster S, Kern WV. Efflux inhibition by selective serotonin reuptake inhibitors in Escherichia coli. J. Antimicrob. Chemother. 66(9), 2057–2060 (2011).
  Medline CASGoogle Scholar
• 12. Nzakizwanayo J, Scavone P, Jamshidi S, Hawthorne JA et al. Fluoxetine and thioridazine inhibit efflux and attenuate crystalline biofilm formation by Proteus mirabilis. Sci. Rep. 7(12222), 1–14 (2017). •• Shows that fluoxetine is a promising strategy for the disassembly of bacterial biofilms.
  Medline CASGoogle Scholar
• 13. Silva RA, Silva CR, Neto JB et al. In vitro anti-Candida activity of selective serotonina reuptake inhibitors against fluconazole-resistant strains and their activity against biofilm-forming isolates. Microb. Pathog. 107, 341–348 (2017).
  Medline CASGoogle Scholar
• 14. Oliveira AS, Martinez-de-Oliveira J, Donders GG, Palmeira-de-Oliveira R, Palmeira-de-Oliveira A. Anti-Candida activity of antidepressants sertraline and fluoxetine: effect upon pre-formed biofilms. Med. Microbiol. Immunol. 207(3-4), 195–200 (2018).
  Medline CASGoogle Scholar
• 15. Jiang L, Zheng L, Sun KA et al. In vitro and in vivo evaluation of the antifungal activity of fluoxetine combined with antifungals against Candida albicans biofilms and oral candidiasis. Biofouling 36(5), 537–548 (2020).
  Medline CASGoogle Scholar
• 16. Pereira TC, Menezes RT, Oliveira HC, Oliveira LD, Scorzoni L. In vitro synergistic effects of fluoxetine and paroxetine in combination with amphothericin B against Cryptococcus neoformans. Pathog. Dis. 79(2), ftab001 (2021).
  Medline CASGoogle Scholar
• 17. Lyte M, Brown DR. Evidence for PMAT- and OCT-like biogenic amine transporters in a probiotic strain of Lactobacillus: implications for interkingdom communication within the microbiota-gut-brain axis. PLOS ONE 13(1), e0191037 (2018).
  MedlineGoogle Scholar
• 18. Josino MA, Silva CR, Neto JB et al. Development and in vitro evaluation of microparticles of fluoxetine in galactomannan against biofilms of S. aureus methicilin resistant. Carbohydr. Polym. 252, 117184 (2021).
  Medline CASGoogle Scholar
• 19. Bandeira TJPG, Castelo-Branco DSCM, Rocha MFG et al. Clinical and environmental isolates of Burkholderia pseudomallei from Brazil: genotyping and detection of virulence gene. Asian. Pac. J. Trop. Med. 10, 945–951 (2017).
  Medline CASGoogle Scholar
• 20. CLSI. Methods for dilution antimicrobial susceptibility tests f or bacteria that grow aerobically; approved standard – Ninth Edition. CLSI document M07-A9. Clinical and Laboratory Standards Institute, PA, USA (2012).
  Google Scholar
• 21. CLSI. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline – Second Edition. CLSI document M45-A3. Clinical and Laboratory Standards Institute, PA, USA (2015).
  Google Scholar
• 22. BrCast. Tabelas de pontos de corte para interpretação de CIMs e diâmetros de halos. Brazilian Committee on Antimicrobial Susceptibility Testing: 2023. https://brcast.org.br/documentos/documentos-3/
  Google Scholar
• 23. Sidrim JJC, Ocadaque CJ, Amando BR et al. Rhamnolipid enhances Burkholderia pseudomallei biofilm susceptibility, disassembly and production of virulence factors. Future Microbiol. 15, 1109–1121 (2020).
  CASGoogle Scholar
• 24. Sidrim JJC, Vasconcelos DC, Riello GB et al. Promethazine improves antibiotic efficacy and disrupts biofilms of Burkholderia pseudomallei. Biofouling 33(1), 88–97 (2017).
  Medline CASGoogle Scholar
• 25. Muhammad MH, Idris AL, Fan X et al. Beyond risk: bacterial biofilms and their regulating approaches. Front. Microbiol. 11(928), 1–20 (2020).
  MedlineGoogle Scholar
• 26. Yin W, Wang Y, Liu L, He J. Biofilms: the microbial “protective clothing” in extreme environments. Int. J. Mol. Sci. 20(14), 3423 (2019).
  Medline CASGoogle Scholar
• 27. Hadera M, Mehari S, Basha NS, Amha ND, Berhane Y. Study on antimicrobial potential of selected non-antibiotics and its interaction with conventional antibiotics. J. Pharm. Biosci. 6(1), 1–7 (2018).
  CASGoogle Scholar
• 28. Das S, Basak R, Roy S. Screening of antimicrobial effect of some non-antibiotics (anti-hypertensive) against some selected microorganisms. Ind. Res. J. Pharm. Sci. 4(3), 1068–1079 (2017).
  CASGoogle Scholar
• 29. Sousa AK, Rocha JE, Souza TG et al. New roles of fluoxetine in pharmacology: antibacterial effect and modulation of antibiotic activity. Microb. Pathog. 123, 368–371 (2018). •• Shows that fluoxetine is a promising strategy for modulation of antibiotic activity.
  MedlineGoogle Scholar
• 30. Neto JB, Josino MA, Silva CR et al. A mechanistic approach to the in-vitro resistance modulating effects of fluoxetine against meticillin resistant Staphylococcus aureus strains. Microb. Pathog. 127, 335–340 (2019).
  MedlineGoogle Scholar
• 31. Schweizer HP. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery. Expert Opin. Drug. Discov. 7(7), 633–642 (2012).
  Medline CASGoogle Scholar
• 32. Oliveira AS, Gaspar CA, Palmeira-de-Oliveira R, Martinez-de-Oliveira J, Palmeira-de-Oliveira A. Anti-Candida activity of fluoxetine alone and combined with fluconazole: a synergistic action against fluconazole-resistant strains. Antimicrob. Agents Chemother. 58(7), 4224–4226 (2014).
  MedlineGoogle Scholar
• 33. Foletto VS, Serafin MB, Bottega A et al. Repositioning of fluoxetine and paroxetine: study of potential antibacterial activity and its combination with ciprofloxacin. Med. Chem. Res. 29, 556–563 (2020). •• Shows that fluoxetine is a promising strategy for modulation of antibiotic activity.
  CASGoogle Scholar
• 34. Jin M, Lu J, Chen Z et al. Antidepressant fluoxetine induces multiple antibiotics resistance in Escherichia coli via ROS-mediated mutagenesis. Environ. Int. 120, 421–430 (2018).
  Medline CASGoogle Scholar
• 35. Alav I, Sutton JM, Rahman KM. Role of bacterial efflux pumps in biofilm formation. J. Antimicrob. Chemother. 73(8), 2003–2020 (2018).
  Medline CASGoogle Scholar
• 36. Dusman E, Almeida IV, Mariucii RG, Mantovani MS, Vicentini VE. Cytotoxicity and mutagenicity of fluoxetine hydrochloride (Prozac), with or without vitamins A and C, in plant and animal model systems. Genet. Mol. Res. 13(1), 578–589 (2014).
  Medline CASGoogle Scholar
• 37. Rosetti M, Frasnelli M, Tesei A, Zoli W, Conti M. Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells. J. Exp. Ther. Oncol. 6(1), 23–29 (2006).
  Medline CASGoogle Scholar
• 38. Tekintas Y, Temel A, Ates A et al. Antifungal and antibiofilm activities of selective serotonin reuptake inhibitors alone and in combination with fluconazole. Turk. J. Pharm. Sci. 17(6), 667–672 (2020).
  Medline CASGoogle Scholar
• 39. Gu W, Guo D, Zhang L, Xu D, Sun S. The synergistic effect of azoles and fluoxetine against resistant Candida albicans strains is attributed to attenuating fungal virulence. Antimicrob. Agents Chemother. 60(10), 6179–6188 (2016).
  MedlineGoogle Scholar